Johnson & Johnson (J&J) MedTech has today announced the launch of the Cereglide 92 catheter system—a next-generation 0.092-inch catheter with the Innerglide 9 delivery aid, indicated for use in facilitating the insertion and guidance of interventional devices in the neurovascular system. The device is now commercially available in the USA.
Cereglide 92 is described by J&J as a 0.092-inch inner diameter catheter system that allows physicians to achieve large distal access and is designed to provide flow reduction in the M1 when inserting devices for the revascularisation of patients with acute ischaemic stroke. The larger lumen also provides distal support for multiple neurovascular tools when treating aneurysms and other haemorrhagic complications, a company press release adds, also noting that Cereglide 92 is the latest catheter in J&J’s growing catheter portfolio designed to integrate with its stroke solutions, such as Cereglide 71, Prowler EX and Embotrap III.
Cereglide 92 features design elements including the co-packaged Innerglide 9 delivery aid, a 0.092-inch inner diameter, full catheter visibility with Brite-Line technology, and TruCourse technology, which increases distal tip flexibility to aid in catheter trackability. The system tracks to the M1 and provides large distal placement for procedural control along with full catheter visibility under fluoroscopy, according to J&J’s release.
“Vessel tortuosity and other anatomical challenges are present in approximately 50% of mechanical thrombectomy cases, which can increase procedure time or prevent ability to treat,” said Brian Jankowitz (JFK University Medical Center, Edison, USA). “As an early user of Cereglide 92 and Innerglide 9, this super large-bore catheter system helps provide quick and seamless access to the M1 with the benefit of flow control, allowing us to rapidly reperfuse the patient and extend the benefits of next-generation stroke technology to more patients.”
Devices within J&J MedTech’s Neurovascular portfolio are developed using expert stroke science insights from its Neuro Thromboembolic Initiative (NTI), and the result—as stated by the company—is devices that have been tested in models that recreate real-world scenarios and seek to further address unmet clinical needs.
“Johnson & Johnson MedTech is continuing to innovate to help address the access challenges physicians face during mechanical thrombectomy procedures with the launch of Cereglide 92,” said Mark Dickinson, worldwide president of Neurovascular at J&J MedTech. “The Cereglide 92 catheter system is the latest innovation in our Cereglide and ischaemic stroke suite of technologies designed to assist physicians in treating their patients and maximising procedural outcomes, to ultimately change the trajectory of stroke.”
